Results 21 to 30 of about 87,478 (258)

The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats

Brazilian Journal of Medical and Biological Research, 2021
It is known that the combined use of antibiotics, such as isoniazid and rifampicin, in the treatment of tuberculosis causes oxidative kidney damage. The aim of this study was to biochemically and histopathologically investigate the effect of lycopene on ...
F. Bedir, H. Kocaturk, O. Turangezli, E. Sener, S. Akyuz, F.B. Ozgeris, B. Dabanlioglu, H. Suleyman, D. Altuner, B. Suleyman   +9 more
doaj   +1 more source

Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance. [PDF]

, 2018
Mycobacterium tuberculosis is a serious human pathogen threat exhibiting complex evolution of antimicrobial resistance (AMR). Accordingly, the many publicly available datasets describing its AMR characteristics demand disparate data-type analyses ...
Anand, Amitesh, Catoiu, Edward, Dillon, Nicholas, Heckmann, David, Kavvas, Erol S, Mih, Nathan, Monk, Jonathan M, Nizet, Victor, Palsson, Bernhard O, Seif, Yara, Yang, Laurence, Yurkovich, James T   +11 more
core   +2 more sources

Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in Mycobacterium tuberculosis

International Journal of Mycobacteriology, 2017
Background: Tuberculosis is one of the most prevalent diseases in Pakistan. Pakistan has the highest burden of MDR-TB in the Eastern Mediterranean region. Ethionamide is an anti-tuberculous drug frequently used to treat MDR-TB.
Salima Qamar, Joveria Q Farooqi, Kausar Jabeen, Rumina Hasan   +3 more
doaj   +1 more source

A Radioimmunoassay for Isoniazid

Clinical Chemistry, 1975
Abstract A sensitive radioimmunoassay is described, for measuring isoniazid in therapeutic and subtherapeutic concentrations. This radioimmunoassay was used in an exploratory clinical study to measure, as a function of time, the concentration of this drug in plasma of patients receiving isoniazid therapy.
R, Schwenk, K, Kelly, K S, Tse, A H, Sehon   +3 more
openaire   +2 more sources

Recurrent Cutaneous Tuberculosis in an Immunocompetent 7-Year-Old Male [PDF]

, 2018
Cutaneous tuberculosis (TB) makes up a small proportion of the 10.4 million cases around the world. Although it is more commonly found in the developing world, cutaneous TB is rarely reported in the developed countries.
Austin, Dena, Galvis, Alvaro, Jaiswal, Vidyasagar, Nakamura, Craig, Pecson, Iris   +4 more
core   +2 more sources

Rationing tests for drug-resistant tuberculosis - who are we prepared to miss? [PDF]

, 2016
BACKGROUND: Early identification of patients with drug-resistant tuberculosis (DR-TB) increases the likelihood of treatment success and interrupts transmission.
A Faustini, A Pantoja, A Pooran, A Vassall, C Fitzpatrick, D Martínez, D Menzies, DAJ Moore, DAJ Moore, David A. J. Moore, E Tortoli, EA Kendall, EL Corbett, GJ Churchyard, JC Feres, Jon S. Friedland, Jorge Coronel, K Kliiman, KAK Angeby, L Caviedes, Laura J. Martin, Louis Grandjean, Luz Caviedes, MA Espinal, Martha H. Roper, O Oxlade, P Miotto, PG Suárez, PT Kent, Robert H. Gilman, SS Shin, V Boonsarngsuk, World Health Organization, World Health Organization, World Health Organization, World Health Organization   +35 more
core   +4 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

Molecules, 2022
Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy.
Nguyen Ky Anh, Pham My Tung, Min Jung Kim, Nguyen Phuoc Long, Yong-Soon Cho, Dong-Hyun Kim, Jae-Gook Shin   +6 more
doaj   +1 more source

Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi

Frontiers in Public Health, 2020
Background: Pellagra is caused by niacin (vitamin B3) deficiency and manifested by a distinctive dermatitis. Isoniazid is critical for treating tuberculosis globally and is a component of most regimens to prevent tuberculosis. Isoniazid may contribute to
Scott A. Nabity, Kelvin Mponda, Steve Gutreuter, Diya Surie, Anne Williams, Anne Williams, Andrea J. Sharma, Elizabeth R. Schnaubelt, Rebekah E. Marshall, Hannah L. Kirking, Suzgo B. Zimba, Joram L. Sunguti, Laphiod Chisuwo, Mabvuto J. Chiwaula, Jesse F. Gregory, Robin da Silva, Michael Odo, Andreas Jahn, Thokozani Kalua, Rose Nyirenda, Belaineh Girma, James Mpunga, Nicole Buono, Alice Maida, Evelyn J. Kim, Laurence J. Gunde, Tigest F. Mekonnen, Andrew F. Auld, Adamson S. Muula, John E. Oeltmann   +29 more
doaj   +1 more source

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Emerging Infectious Diseases, 2006
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation.
Maria Elvira Balcells, Sara L. Thomas, Peter Godfrey-Faussett, Alison D. Grant   +3 more
doaj   +1 more source